High Quality Proteins Supplier
With over 20 years of experience in peptide synthesis, we have advanced peptide synthesis instruments, professional team, and extensive expertise in peptide synthesis and purification processes. Our advanced peptide synthesis platform and quality control system work together to provide clients with high-quality products.
Antibody-Drug Conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, and peptide linkers play a pivotal role in their stability, efficacy, and safety. This article explores the importance of peptide linkers in ADC design and highlights the expertise of KS-V Peptide in developing high-performance linker solutions.
Controlled Payload Release
Peptide linkers enable selective drug release in the tumor microenvironment through enzymatic cleavage or pH-sensitive mechanisms, minimizing off-target toxicity.
Enhanced Stability
Optimized peptide linkers improve ADC stability in systemic circulation, preventing premature payload release and ensuring efficient drug delivery.
Customizable Design
Linker chemistry can be tailored to match specific antibodies, payloads, and therapeutic requirements, allowing for precision-engineered ADCs.
As a trusted innovator in peptide technology, KS-V Peptide offers:
Protease-cleavable & non-cleavable linkers for diverse ADC platforms
Site-specific conjugation technologies for homogeneous ADC production
GMP-grade manufacturing with strict quality control
Next-generation peptide linkers are driving advancements in:
✔ Improved therapeutic windows (higher efficacy, lower toxicity)
✔ Novel conjugation strategies for better DAR (Drug-to-Antibody Ratio) control
✔ Dual-payload ADCs enabled by smart linker systems
Elevate your ADC development with KS-V Peptide’s cutting-edge peptide linker solutions.
Learn more: https://www.ks-vpeptide.com/peptide-linkers-for-adc
Connect on LinkedIn: https://www.linkedin.com/company/ks-v-peptide/